NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
NEKTAR THERAPEUTICS
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Aug 14, 2026
$36.64+0.86 (+2.40%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
NEKTAR THERAPEUTICS revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-cash royalty revenue related to the sales of future royalties | $54.93M | $64.27M | $68.92M | $69.79M | $77.75M | $48.56M | $36.30M | $33.31M | $30.53M | $30.16M | 99.5% | -14.5% |
| NonCash Royalties | $54.90M | $64.30M | $68.90M | – | – | – | – | – | – | – | 99.4% | -14.6% |
| License, collaboration and other revenue | $300.00K | $597.00K | $520.00K | $1.91M | $436.00K | $55.85M | $16.98M | $1.10B | $210.97M | $60.38M | 0.5% | -49.7% |
| Product sales | $0 | $33.56M | $20.68M | $20.35M | $23.73M | $17.50M | $20.12M | $20.77M | $32.69M | $55.35M | 0.0% | -100.0% |
| Royalty revenue | – | – | – | $0 | $0 | $31.00M | $41.22M | $41.98M | $33.53M | $19.54M | – | – |
| Cash And NonCash Royalties | – | – | $68.90M | $69.80M | $77.70M | $79.60M | $77.50M | – | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of Nektar Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.